Long-term (+ 3-Year) Safety and Efficacy Data for the Port Delivery System: Interim Analysis Results of the Portal Extension Study of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

The Portal extension trial (NCT03683251) evaluates the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) 100 mg/mL with fixed refill-exchanges every 24 weeks (PDS Q24W) for neovascular age-related macular degeneration. Here we present interim longer-term efficacy data from patients from Ladder (NCT02510794) who enrolled in the Portal trial, including patients who switched from monthly intravitreal ranibizumab 0.5 mg injections in Ladder to the PDS Q24W in Portal. Long-term pooled safety data from Ladder, Archway (NCT03677934), and Portal are also reported.